Meanwhile, scientists were racing to produce a vaccine against the new flu strain, but the shots -- if needed at all -- wouldn't be available until fall at the earliest, U.S. health officials have said.
"We think 600 million doses is achievable in a six-month timeframe" from that fall start, U.S. Health and Human Services Assistant Secretary Craig Vanderwagen told lawmakers last week.
On Friday, U.S. health officials told reporters that six countries -- the United States, Canada, the Netherlands, Mexico, Germany and New Zealand -- have all shared samples of the virus for testing to further the vaccine effort.
"The good news is that the genes of all of the viruses we have examined to date are 99 to 100 percent identical," Cox said. "This means that it will be somewhat easier for us to produce an influenza vaccine."
"We are aggressively taking the very early steps that are necessary for vaccine manufacture should a decision be made go ahead and ramp up to full-scale production," Cox added.
The current plan is to have vaccine manufacturers complete production of next year's seasonal flu vaccine, then, if necessary, switch to the production of the H1N1 vaccine, Schuchat said.
The flu strain is a combination of pig, bird and human viruses, prompting worries from health officials that humans may have no natural immunity to the pathogen.
Meanwhile, the U. S. Food and Drug Administration and the Federal Trade Commission warned consumers Friday to avoid Internet sites and other promotions that offer products claiming to diagnose, prevent, treat or cure the swine flu virus.
"Consumers who purchase products to treat the novel 2009 H1N1 virus that are not approved, cleared or authorized by t
All rights reserved